



RECEIVED
CENTRAL FAX CENTER
NOV 10 2011

ATTORNEYS AT LAW
WASHINGTON HARBOUR
3000 K STREET, N.W.
SUITE 600
WASHINGTON, D.C. 20007-5109
202.672.5300
202.672.5399
WWW.FOLEY.COM

sbent@foley.com
202.672.5404

MEMORANDUM

CLIENT-MATTER NUMBER
060348-0149

TO: Anoop Kumar Singh,
Examiner U.S. Patent and Trademark Office
Art Unit 1632

FROM: Stephen A. Bent,
Reg. No. 29786 Foley & Lardner LLP

DATE: November 10, 2011

RE: *Request for Teleconference on Proposal for
Claim Revisions in U.S. SN 10/588028*

Dear Dr. Singh,

Would you be willing to receive my call, at your convenience, to discuss a proposed revision, illustrated below, to the main claim of the captioned application?

If so, please let me know when and where I can reach you for this purpose.

Thanks for your attention to this request.

SAB

8. A targeted drug delivery method that comprises

- (A) *providing a composition comprising (i) intact, bacterially derived minicells that are approximately 400 nm in diameter and that are loaded with a therapeutically significant concentration of a ~~small-molecule-drug~~ chemotherapeutic agent and (ii) bispecific ligands having specificity for a mammalian cell surface receptor and specificity for said minicells, wherein said composition is free of membrane blebs of 200 nm or less in size; and*
- (B) *contacting said composition with non-phagocytic mammalian cells, such that (i) said bispecific ligands cause said minicells to bind to said mammalian cells, (ii) said minicells are engulfed by said mammalian cells, and (iii) said ~~small-molecule-drug~~ chemotherapeutic agent is released into the cytoplasm of said mammalian cells.*